These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 19411846)

  • 1. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.
    Vaseva AV; Marchenko ND; Moll UM
    Cell Cycle; 2009 Jun; 8(11):1711-9. PubMed ID: 19411846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
    Lee SY; Shin SJ; Kim HS
    Int J Oncol; 2013 Mar; 42(3):1027-35. PubMed ID: 23314357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nutlin kills cancer cells via mitochondrial p53.
    Morselli E; Galluzzi L; Kepp O; Kroemer G
    Cell Cycle; 2009 Jun; 8(11):1647-8. PubMed ID: 19448434
    [No Abstract]   [Full Text] [Related]  

  • 8. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
    Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
    Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
    Aziz MH; Shen H; Maki CG
    Oncogene; 2011 Nov; 30(46):4678-86. PubMed ID: 21643018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
    Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
    Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutlin-3 induces HO-1 expression by activating JNK in a transcription-independent manner of p53.
    Choe YJ; Lee SY; Ko KW; Shin SJ; Kim HS
    Int J Oncol; 2014 Mar; 44(3):761-8. PubMed ID: 24366007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
    Hu B; Gilkes DM; Farooqi B; Sebti SM; Chen J
    J Biol Chem; 2006 Nov; 281(44):33030-5. PubMed ID: 16905541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
    Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Nacheva EP; Howard-Reeves JD; Duke VM; Kottaridis PD; Cwynarski K; Vassilev LT; Wickremasinghe RG
    Blood; 2008 Nov; 112(9):3827-34. PubMed ID: 18682598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.